The Manila Times

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s giredestrant becomes the first oral SERD to show superior invasive disease-free survival in early breast cancer

At interim analysis, giredestrant demonstrated a statistically significant and clinically meaningful benefit versus ...
European Medical Journal

Association Between Ultra-Processed Food Consumption and Risk of Developing Depression in Adults: A Systematic Review

Depression, also known as major depressive disorder (MDD), is marked by a loss of interest or pleasure in activities and ...

Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment

TONMYA is now available by prescription and available for pharmacy ordering nationwideTONMYA is the first FDA-approved treatment for fibromyalgia ...

OS Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update

Type C Meeting with US FDA set for December 11, 2025 to address key items following August 27, 2025 End of Phase 2 Meeting regarding Phase 2b clinical trial of OST-HER2: prevention or delay of recurre ...

Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA (cyclobenzaprine HCl sublingual tablets) as a First-in-Class ...

TONMYA was approved by the FDA on August 15, 2025.
JCN Newswire

JBM Healthcare Announces FY2026 Interim Results

Limited (“JBM Healthcare” or the “Company”, Stock Code: 2161, together with its subsidiaries, the “Group”), a leading branded healthcare products marketer and distributor in Hong Kong, today announced ...